Detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis using the quantamatrix multiplexed assay platform system

Hye Young Wang, Young Uh, Seoyong Kim, Eunjin Cho, Jong Seok Lee, Hyeyoung Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. Methods: A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. Results: Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4% (106/110; 95% confidence interval [CI] 0.9072-0.9888) and 80.0% (72/90; 95% CI 0.7052-0.8705), respectively, for RIF resistance and 75.0% (108/144; 95% CI 0.6731-0.8139) and 96.4% (54/56; 95% CI 0.8718-0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6% (121/124; 95% CI 0.9282-0.9949) and 99.1% (109/110; 95% CI 0.9453-1.0000), respectively. Comparison between the QMAP system and gene sequencing analysis showed an overall agreement of 100% for RIF resistance (110/110; 95% CI 0.9711-1.0000) and INH resistance (124/124; 95% CI 0.9743-1.0000). Conclusions: The QMAP system may serve as a useful screening method for identifying and accurately discriminating MTBC from non-tuberculous mycobacteria, as well as determining RIF- and INH-resistant MTB strains.

Original languageEnglish
Pages (from-to)569-577
Number of pages9
JournalAnnals of laboratory medicine
Volume38
Issue number6
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Isoniazid
Rifampin
Mycobacterium tuberculosis
Assays
Confidence Intervals
Genes
Pharmaceutical Preparations
MDR Genes
Multidrug-Resistant Tuberculosis
Bioassay
Testing
Public health
Mycobacterium
Korea
Biological Assay
Screening
Tuberculosis
Emergencies
Public Health
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Wang, Hye Young ; Uh, Young ; Kim, Seoyong ; Cho, Eunjin ; Lee, Jong Seok ; Lee, Hyeyoung. / Detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis using the quantamatrix multiplexed assay platform system. In: Annals of laboratory medicine. 2018 ; Vol. 38, No. 6. pp. 569-577.
@article{97f8c1ed2da540b287b68a2a25f6f120,
title = "Detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis using the quantamatrix multiplexed assay platform system",
abstract = "Background: The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. Methods: A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. Results: Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4{\%} (106/110; 95{\%} confidence interval [CI] 0.9072-0.9888) and 80.0{\%} (72/90; 95{\%} CI 0.7052-0.8705), respectively, for RIF resistance and 75.0{\%} (108/144; 95{\%} CI 0.6731-0.8139) and 96.4{\%} (54/56; 95{\%} CI 0.8718-0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6{\%} (121/124; 95{\%} CI 0.9282-0.9949) and 99.1{\%} (109/110; 95{\%} CI 0.9453-1.0000), respectively. Comparison between the QMAP system and gene sequencing analysis showed an overall agreement of 100{\%} for RIF resistance (110/110; 95{\%} CI 0.9711-1.0000) and INH resistance (124/124; 95{\%} CI 0.9743-1.0000). Conclusions: The QMAP system may serve as a useful screening method for identifying and accurately discriminating MTBC from non-tuberculous mycobacteria, as well as determining RIF- and INH-resistant MTB strains.",
author = "Wang, {Hye Young} and Young Uh and Seoyong Kim and Eunjin Cho and Lee, {Jong Seok} and Hyeyoung Lee",
year = "2018",
month = "1",
day = "1",
doi = "10.3343/alm.2018.38.6.569",
language = "English",
volume = "38",
pages = "569--577",
journal = "Annals of Laboratory Medicine",
issn = "2234-3806",
publisher = "Seoul National University",
number = "6",

}

Detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis using the quantamatrix multiplexed assay platform system. / Wang, Hye Young; Uh, Young; Kim, Seoyong; Cho, Eunjin; Lee, Jong Seok; Lee, Hyeyoung.

In: Annals of laboratory medicine, Vol. 38, No. 6, 01.01.2018, p. 569-577.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis using the quantamatrix multiplexed assay platform system

AU - Wang, Hye Young

AU - Uh, Young

AU - Kim, Seoyong

AU - Cho, Eunjin

AU - Lee, Jong Seok

AU - Lee, Hyeyoung

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. Methods: A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. Results: Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4% (106/110; 95% confidence interval [CI] 0.9072-0.9888) and 80.0% (72/90; 95% CI 0.7052-0.8705), respectively, for RIF resistance and 75.0% (108/144; 95% CI 0.6731-0.8139) and 96.4% (54/56; 95% CI 0.8718-0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6% (121/124; 95% CI 0.9282-0.9949) and 99.1% (109/110; 95% CI 0.9453-1.0000), respectively. Comparison between the QMAP system and gene sequencing analysis showed an overall agreement of 100% for RIF resistance (110/110; 95% CI 0.9711-1.0000) and INH resistance (124/124; 95% CI 0.9743-1.0000). Conclusions: The QMAP system may serve as a useful screening method for identifying and accurately discriminating MTBC from non-tuberculous mycobacteria, as well as determining RIF- and INH-resistant MTB strains.

AB - Background: The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. Methods: A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. Results: Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4% (106/110; 95% confidence interval [CI] 0.9072-0.9888) and 80.0% (72/90; 95% CI 0.7052-0.8705), respectively, for RIF resistance and 75.0% (108/144; 95% CI 0.6731-0.8139) and 96.4% (54/56; 95% CI 0.8718-0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6% (121/124; 95% CI 0.9282-0.9949) and 99.1% (109/110; 95% CI 0.9453-1.0000), respectively. Comparison between the QMAP system and gene sequencing analysis showed an overall agreement of 100% for RIF resistance (110/110; 95% CI 0.9711-1.0000) and INH resistance (124/124; 95% CI 0.9743-1.0000). Conclusions: The QMAP system may serve as a useful screening method for identifying and accurately discriminating MTBC from non-tuberculous mycobacteria, as well as determining RIF- and INH-resistant MTB strains.

UR - http://www.scopus.com/inward/record.url?scp=85054877679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054877679&partnerID=8YFLogxK

U2 - 10.3343/alm.2018.38.6.569

DO - 10.3343/alm.2018.38.6.569

M3 - Article

C2 - 30027701

AN - SCOPUS:85054877679

VL - 38

SP - 569

EP - 577

JO - Annals of Laboratory Medicine

JF - Annals of Laboratory Medicine

SN - 2234-3806

IS - 6

ER -